11.49
-1.96%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About China Isotope & Radiation
Its shares trade on HKEX under the ticker 1763.HK. It has been listed since 6 July 2018. In the fiscal year to 31 December 2025, it reported revenue of CN¥7.00bn and net income of CN¥319.0m. At that date it held total assets of CN¥15.72bn and shareholders' equity of CN¥5.23bn.
China Isotope & Radiation Corp. engages in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications. The company is headquartered in Beijing, Beijing. The company went IPO on 2018-07-06. The firm also provides radiation sterilization services. The firm is also involved in the design, manufacture and installation of Gama ray irradiation devices. The firm opeartes its businesse mainly through four segments, including the Pharmaceuticals segment, the Radiological Products segment, the Irradiation segment and the Independent Medical Laboratory Services and Others segment, with the Pharmaceuticals segment as the core segment. The Pharmaceuticals segment is engaged in the development, manufacture and sale of radiopharmaceuticals, the Kit for Urea Breath Test and testing instruments, as well as in vitro immunodiagnostic reagents and boxes for imaging diagnosis and treatment.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 6 Jul 2018
- Employees
- 3,030
- Website
- china-isotope.com ↗
Leadership
Pay as last reported
- Mr. Yongjian HanExecutive Chairman of the Board
- Mr. Laishui WuChief Accountant, Chief Legal Officer
- Mr. Junqi ZhangGeneral Manager, Executive Director, since 2023
- Ms. Sau In KwanJoint Company Secretary
- Ms. Cangren WangJoint Company Secretary
- Ms. Yingying HuoEmployee Representative Director
- Ms. Jinyu ChangNon-Executive Director
- Mr. Zan ChenNon-Executive Director
- Mr. Jianmin DingNon-Executive Director
- Ms. Xiuhong LiuNon-Executive Director
- Mr. Rui AnNon-Executive Independent Director
- Ms. Jingshan ChenNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- China Isotope & Radiation Corp (CIRC) benefits from its strong market presence and reputation in the industry.
- The company possesses advanced technology and expertise in producing and distributing isotopes and radiation-related products.
- CIRC has a diverse product portfolio, catering to various industries such as medical, industrial, and research sectors.
Weaknesses
- CIRC faces intense competition from domestic and international players in the market.
- The company may have limitations in terms of product innovation and differentiation, which could impact its market position.
- CIRC's dependence on government regulations and approvals for its products may introduce delays and uncertainties.
Opportunities
- The increasing demand for radiopharmaceuticals and radiation-related medical treatments provides growth opportunities for CIRC.
- Expansion into international markets can help CIRC diversify its customer base and reduce dependence on the domestic market.
- Collaborations and partnerships with research institutes and medical facilities can lead to the development of innovative products and technologies.
Threats
- Stringent government regulations and compliance requirements can pose challenges for CIRC's operations and product development.
- Economic uncertainties and fluctuations in market conditions could impact the demand for CIRC's products.
- Potential emergence of substitute technologies or alternative treatment options may pose a threat to CIRC's market position.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.